Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Alebund Pharmaceuticals (Jiangsu) PB Ratio Related Terms
Alebund Pharmaceuticals (Jiangsu) PB Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alebund Pharmaceuticals (Jiangsu) PB Ratio Chart
Alebund Pharmaceuticals (Jiangsu) Annual Data
Trend
Dec24
Dec25
PB Ratio
0.00
0.00
Alebund Pharmaceuticals (Jiangsu) Semi-Annual Data
Dec24
Dec25
PB Ratio
0.00
0.00
HKSE:09637 vs LLY, JNJ, ABBV: PB Ratio Comparison
For the Drug Manufacturers - General subindustry, Alebund Pharmaceuticals (Jiangsu)'s PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alebund Pharmaceuticals (Jiangsu) PB Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Alebund Pharmaceuticals (Jiangsu)'s PB Ratio distribution charts can be found below:
* The bar in red indicates where Alebund Pharmaceuticals (Jiangsu)'s PB Ratio falls into.
Alebund Pharmaceuticals (Jiangsu) PB Ratio Calculation
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Alebund Pharmaceuticals (Jiangsu) (HKSE:09637) has a PB Ratio of 15.28 as of Sep. 10, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Alebund Pharmaceuticals (Jiangsu) and its competitors. According to the industry distribution chart, Alebund Pharmaceuticals (Jiangsu) ranks #868 out of 919 companies in the Drug Manufacturers industry, placing it in the top 94.5%.
Is Alebund Pharmaceuticals (Jiangsu)'s PB Ratio too high?
Alebund Pharmaceuticals (Jiangsu)'s current PB Ratio is 15.28. The Drug Manufacturers industry median PB Ratio is 1.96. Alebund Pharmaceuticals (Jiangsu)'s value of 15.28 is 679.6% above this industry median. Based on the distribution chart, Alebund Pharmaceuticals (Jiangsu) ranks #868 out of 919 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Alebund Pharmaceuticals (Jiangsu) has a GF Score™ of 5/100, reflecting its overall financial health beyond just this single metric.
How does Alebund Pharmaceuticals (Jiangsu)'s PB Ratio compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Alebund Pharmaceuticals (Jiangsu) ranks #868 out of 919 companies for PB Ratio. This places Alebund Pharmaceuticals (Jiangsu) in the lower half of its industry. The industry median PB Ratio is 1.96. Alebund Pharmaceuticals (Jiangsu)'s value of 15.28 is 679.6% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Drug Manufacturers company?
The median PB Ratio among Drug Manufacturers companies is 1.96, based on 919 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Alebund Pharmaceuticals (Jiangsu)'s current PB Ratio of 15.28 is 679.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Alebund Pharmaceuticals (Jiangsu) and its competitors. For the Drug Manufacturers industry, the median PB Ratio is 1.96 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Alebund Pharmaceuticals (Jiangsu)'s current PB Ratio is 15.28. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alebund Pharmaceuticals (Jiangsu) stock overvalued right now?
Alebund Pharmaceuticals (Jiangsu) (HKSE:09637) has a current PB Ratio of 15.28. The current PB Ratio is 15.28 and 679.6% above the Drug Manufacturers industry median of 1.96. Alebund Pharmaceuticals (Jiangsu)'s overall GF Score™ is 5/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Alebund Pharmaceuticals (Jiangsu) (HKSE:09637), the current PB Ratio is 15.28 as of Sep. 10, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Alebund Pharmaceuticals (Jiangsu) Ltd is a biopharmaceutical company. Along with its subsidiaries, the company is principally engaged in the development, manufacturing, and commercialization of renal products. Its product portfolio in clinical and preclinical stages consists of one Core Product AP301 and six other product candidates, including one late-clinical-stage product candidate AP306, one early-clinical-stage product candidate (AP303), and four preclinical product candidates (AP308, AP304, AP305, and AP307). The company generated revenue from the sales of Mircera in China, a product used in the treatment of renal anemia.
5GF Score
Get the complete analysis for HKSE:09637
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:09637 has been successfully added to your 
